Report reviews the utility of allergy-specific immunotherapy in allergic rhinoconjunctivitis.
Research concludes that mast cells are a potential therapeutic target in corneal neovascularization treatment.
Researchers compare allergic responses, including conjunctivitis, from various allergens.
Telemedicine offers new possibilities in the diagnosis and follow-up care of ocular surface diseases.
A study reviews the neonatal outcomes of exposure to ophthalmic corticosteroids.
The medication improved both ocular and nasal allergy symptoms.
Investigators identify the advantages and disadvantages of questionnaires designed to quantify the impact of different etiologies of ocular allergy.
Researchers show how aggNET-limiting therapies can manage meibomian gland dysfunction.
Researchers analyzed real-world evidence on the safety and efficacy of dupilumab to treat atopic dermatitis.
Ragweed sublingual immunotherapy tablet improved symptoms and decreased the need for rescue medication in the largest allergy immunotherapy trial in children with ragweed allergic rhinitis with or without conjunctivitis.
Diclofenac sodium topical gel and olopatadine HCl ophthalmic drops will soon be available over-the-counter (OTC) after the the Food and Drug Administration (FDA) switched the status of these products from prescription to nonprescription.
Ragweed sublingual immunotherapy tablets may be an effective treatment option in children with allergic rhinitis with or without conjunctivitis.